Next Article in Journal
Critical Role of the Human ATP-Binding Cassette G1 Transporter in Cardiometabolic Diseases
Next Article in Special Issue
Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation
Previous Article in Journal
The Lactate/Albumin Ratio: A Valuable Tool for Risk Stratification in Septic Patients Admitted to ICU
Previous Article in Special Issue
The Role of Sphingolipids on Innate Immunity to Intestinal Salmonella Infection
Review

“Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer

School of Life Sciences, Faculty of Science, University of Technology Sydney, 15 Broadway, Ultimo, Sydney, NSW 2007, Australia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(9), 1891; https://doi.org/10.3390/ijms18091891
Received: 2 August 2017 / Revised: 29 August 2017 / Accepted: 29 August 2017 / Published: 2 September 2017
(This article belongs to the Special Issue Sphingolipids: Signals and Disease)
Sphingosine kinase (SphK) is a lipid enzyme that maintains cellular lipid homeostasis. Two SphK isozymes, SphK1 and SphK2, are expressed from different chromosomes and several variant isoforms are expressed from each of the isozymes, allowing for the multi-faceted biological diversity of SphK activity. Historically, SphK1 is mainly associated with oncogenicity, however in reality, both SphK1 and SphK2 isozymes possess oncogenic properties and are recognized therapeutic targets. The absence of mutations of SphK in various cancer types has led to the theory that cancer cells develop a dependency on SphK signaling (hyper-SphK signaling) or “non-oncogenic addiction”. Here we discuss additional theories of SphK cellular mislocation and aberrant “dicing and splicing” as contributors to cancer cell biology and as key determinants of the success or failure of SphK/S1P (sphingosine 1 phosphate) based therapeutics. View Full-Text
Keywords: sphingosine kinase (SphK); isozymes; variant isoforms; cancer therapy; sphingosine 1 phosphate (S1P) sphingosine kinase (SphK); isozymes; variant isoforms; cancer therapy; sphingosine 1 phosphate (S1P)
Show Figures

Graphical abstract

MDPI and ACS Style

Haddadi, N.; Lin, Y.; Simpson, A.M.; Nassif, N.T.; McGowan, E.M. “Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer. Int. J. Mol. Sci. 2017, 18, 1891. https://doi.org/10.3390/ijms18091891

AMA Style

Haddadi N, Lin Y, Simpson AM, Nassif NT, McGowan EM. “Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer. International Journal of Molecular Sciences. 2017; 18(9):1891. https://doi.org/10.3390/ijms18091891

Chicago/Turabian Style

Haddadi, Nahal, Yiguang Lin, Ann M. Simpson, Najah T. Nassif, and Eileen M. McGowan 2017. "“Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer" International Journal of Molecular Sciences 18, no. 9: 1891. https://doi.org/10.3390/ijms18091891

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop